The U.S. renal denervation catheter market size was estimated at USD 23.20 million in 2025 and is projected to reach USD 182.70 million by 2033, growing at a CAGR of 29.43% from 2025 to 2033. The growth is driven by the rising prevalence of hypertension and growing awareness about the limitations of pharmacological treatments, increasing clinical evidence supporting the safety and efficacy of renal denervation, and favorable regulatory advancements, such as the recent FDA approval, are further accelerating market adoption.
According to data released by the National Center for Health Statistics and the National Health and Nutrition Examination Survey in October 2024, the prevalence of hypertension among U.S. adults was 23.4% for those aged 18-39, rising to 52.5% for individuals aged 40-59, and reaching 71.6% for those aged 60 and older during the period from August 2021 to August 2023.
The high prevalence of hypertension is one of the primary drivers for the U.S. renal denervation catheter industry. In addition, a growing subset of patients suffers from treatment-resistant hypertension, which does not respond adequately to multiple antihypertensive medications. This widespread burden of disease creates a strong clinical need for alternative therapeutic interventions, such as renal denervation, which offers a non-pharmacological approach to long-term blood pressure control. As awareness and diagnosis rates improve, the eligible patient pool for RDN procedures is expected to expand, further propelling market demand.
This product will be delivered within 2 business days.
According to data released by the National Center for Health Statistics and the National Health and Nutrition Examination Survey in October 2024, the prevalence of hypertension among U.S. adults was 23.4% for those aged 18-39, rising to 52.5% for individuals aged 40-59, and reaching 71.6% for those aged 60 and older during the period from August 2021 to August 2023.
The high prevalence of hypertension is one of the primary drivers for the U.S. renal denervation catheter industry. In addition, a growing subset of patients suffers from treatment-resistant hypertension, which does not respond adequately to multiple antihypertensive medications. This widespread burden of disease creates a strong clinical need for alternative therapeutic interventions, such as renal denervation, which offers a non-pharmacological approach to long-term blood pressure control. As awareness and diagnosis rates improve, the eligible patient pool for RDN procedures is expected to expand, further propelling market demand.
U.S. Renal Denervation Catheter Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2025 to 2033. For this study, the analyst has segmented the U.S. renal denervation catheter market report based on product and end use:Product Outlook (Revenue, USD Million, 2025 - 2033)
- Radiofrequency (RF) Ablation Catheters
- Ultrasound Ablation Catheters
End Use Outlook (Revenue, USD Million, 2025 - 2033)
- Hospitals
- Other
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Renal Denervation Catheter Market Variables, Trends, & Scope
Chapter 4. U.S. Renal Denervation Catheter Market: Product Estimates & Trend Analysis
Chapter 5. U.S. Renal Denervation Catheter Market: End Use Estimates & Trend Analysis
Chapter 6. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Recor Medical, Inc. (Otsuka Medical Devices Co., Ltd.)
- Medtronic
- Boston Scientific Corporation
- MicroPort Scientific Corporation
- EnligHTN, St. Jude Medical (Abbott Laboratories)
- Ablative Solutions, Inc.
